Weighing Cefiderocol and Combination Therapy for Stenotrophomonas

"Weighing Cefiderocol and Combination Therapy for Stenotrophomonas" takes up the most debated recommendation in the guidance and the uncertain evidence behind it. Stenotrophomonas maltophilia exposes the limits of the evidence behind gram-negative treatment more clearly than any other organism, and the panel treats that uncertainty as something to acknowledge rather than conceal. Dr. Pogue first stresses that distinguishing true infection from colonization matters even more here than for Acinetobacter.

He explains that the guidance now recommends cefiderocol first line, driven by consistent preclinical evidence of potent activity and low MICs. By contrast, trimethoprim-sulfamethoxazole, levofloxacin, and minocycline became standard because they tested susceptible, and later pharmacokinetic-pharmacodynamic analyses and animal models showed them performing worse than expected. Dr. Pogue also outlines the rationale for aztreonam-avibactam against the organism's intrinsic enzymes. Still, he urges humility, recalling that cefiderocol once looked equally promising for Acinetobacter. Having seen it fail personally, he pairs cefiderocol with minocycline for critically ill patients with invasive infection, while viewing minocycline alone as reasonable for non-severe infection outside the intensive care unit.

Dr. Shields credits the guidance with organizing retrospective, heterogeneous evidence clouded by uncertainty about the organism's pathogenicity. He suggests anchoring decisions in the host, particularly patients with hematologic malignancies at risk for hemorrhagic pneumonia, for whom cefiderocol is the best of imperfect options. Dr. Haidar praises frequent updates and the guidance's avoidance of dogmatism. Dr. Tamma explains that the guidance suggests two agents initially for seriously ill patients, consolidating to one with improvement, and notes that independent breakpoint organizations share the panel's doubts about older agents. Dr. Pogue observes that, had all of these drugs arrived together, clinicians would likely default to a beta-lactam. Clinicians should treat several approaches as reasonable and discuss the uncertainty candidly.

The conversation moves from the bedside to the hospital system in "Building the Formulary Case for Novel AMR Antibiotics."